-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232

Benzinga·11/06/2026 17:24:50
Listen to the news
Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.